Forgent Power down 21.5% on CFO exit and an 8-K
FPS was the worst name on the list, down 21.5%. On October 22 the company filed an amendment clarifying that CFO Ryan Fiedler's resignation, effective October 21, involved no disagreements over operations or financial practices, and that he stays on in a transitional role until October 30. Alongside that sit two more filings in the list: an 8-K/A covering the officer departure and a separate 8-K carrying Item 2.02, results of operations and financial condition, which the list shows headline-only, so the actual results content isn't in front of me. The GuruFocus piece around the CFO note adds context rather than news: market cap $7.06 billion, price-to-sales of 4.95 against a five-year median of 10.38, a GF Score of 16 out of 100, no insider purchases in twelve months against $649.9 million of insider selling, and seven gurus holding with five trimming versus three adding. Given there's an earnings 8-K in the same batch, the 21.5% drop may well be about the numbers rather than the CFO, and the material here doesn't tell me which.
Vicor down 15.7%, fundamentals improving as the stock falls
VICR fell 15.7%. The Investing.com piece is a retrospective on InvestingPro's June call: the stock was $366.84 in late June when their Fair Value model put intrinsic value at $199.88, implying 45.5% downside, and shares have since fallen 51% to $179.99. What's worth noting is the operating detail in that article, because it cuts the other way: Q3 2026 revenue rose 31% to $560.7 million and EBITDA more than doubled to $166.31 million, versus $426.7 million revenue and $80.07 million EBITDA at the June snapshot. The company also announced AI chip power delivery licensing deals and plans for two new fabs. The article flags CEO and VP insider selling during the decline. Current Fair Value estimate is $170.18, with the stock 5.8% above it.
Nokia down 14.8% despite a strong Q3
NOK fell 14.8%, and nothing in the material explains it. The Q3 print was good: net sales up 9%, operating profit of EUR 605 million, operating margin up 220 basis points to 11.7%. AI and cloud sales surged 123% year over year to 12% of group sales, with order intake up 118% to EUR 1.5 billion. IP networks grew 43%, optical 18% with demand exceeding supply and 800G coherent pluggable volumes more than doubling sequentially. Fixed networks fell 22% on deliberate portfolio pruning of lower-margin ONT volume. Guidance: IP and optical combined growth of 25% to 30% in 2027, Q4 sales up 20% to 24% sequentially. The negatives are real but known: free cash flow of negative EUR 99 million on restructuring and working capital, network infrastructure gross margin down 150 basis points to 41.2% on AI product ramp costs, restructuring charges of roughly EUR 1.1 billion in 2026 with EUR 800-900 million of cash out, and supply chain and component cost pressure across leading-edge nodes and memory. On the call, CEO Justin Hotard said Fab 2 (six-inch indium phosphide, San Jose) is 90% through process development and moving to 24/7, with production entry targeted by year-end and a ramp through 2027. He said the constraint in AI and cloud is supply, not demand, with most of the roughly EUR 5 billion of orders booked over five quarters due within twelve months. CFO Marco Kovarin expects Q4 gross margin better than Q3. Separately, GuruFocus has NOK at a GF Score of 65, price $8.32 against GF Value of $5.02, and seven gurus trimming versus one adding. One caveat worth flagging: two of the items tagged NOK are actually TSP Capital 13F notes about Maui Land & Pineapple and Global Water Resources, which only mention Nokia as a top holding of that firm. They tell you nothing about Nokia.
Coherent down 12.5% in a tech sell-off
COHR fell 12.5% to around $207.82, against a 52-week range of $115 to $440. The GuruFocus coverage frames it as part of a broader tech pullback on October 22, naming GE Vernova down 11.22% and Flex down 10.03% the same day, with no company-specific catalyst given. Valuation detail: GF Value of $104.66 versus the current price, price-to-sales of 5.76 against a historical median of 2.23, trailing P/E of 50.5 versus a five-year median of 76.6, forward P/E of 22.1. GF Score of 78, strong on growth (9/10) and momentum (9/10), weak on valuation (1/10). Insiders sold roughly $1.12 billion over twelve months with no buying, and of 13 gurus holding, 12 trimmed and 3 added. There's also a headline-only note on Thursday option activity listing COHR alongside JBLU and LULU.
TeraWulf down 11.3% into earnings
WULF fell 11.3%. The piece covers option positioning ahead of earnings: volume of 62,000 contracts with calls heavily outnumbering puts for a put/call ratio of 0.16 against an average of 0.44, while implied volatility rose to 104.02 and the put-call skew steepened. The stock was quoted down 97 cents near $11.79. Fundamentals in the article are poor: GF Score 39, financial strength 2/10, debt-to-equity 35.56, Altman Z of -0.76, trailing EPS of -4.40, price-to-sales of 30.25 against a 12.82 median, GF Value $6.01. Insiders sold $36.1 million over twelve months against $0.4 million bought. Momentum ranks 8/10.
Astera Labs down 11.1% with ETFs still buying
ALAB fell 11.1%. The only substantive item is an ETF flow note covering October 21, before the drop: twenty ETFs added and seven cut, net buying of $31.1 million, extending a four-day inflow streak that included $72.2 million on Oct 20 and $47.2 million on Oct 19, after a $29.2 million outflow on Oct 15. SOXX did the bulk, adding 101,796 shares worth $29.5 million. Company figures given: trailing revenue $1.20 billion, up 85.4%, gross margin 75.1%, net margin 30.7%, P/E 126.94, P/S 39, market cap $44.7 billion, GF Score 14. There's also a headline-only Thursday option activity item naming ALAB.
SpaceX down 9.1% on spending and dilution worries
SPCX fell 9.1%, closing down $14.56 at $144.75 per the GuruFocus piece, which attributes the move to investors shifting focus from a solid Q3 to the capital bill behind the next phase: rocket infrastructure, satellite networks and compute capacity, plus the risk of share issuance diluting holders, and the uncertainty around a proposed Tesla combination. The same day, an Investing.com piece explains the opposite move premarket, when the stock rose 2.0% on a Bloomberg report that SpaceX is in talks with cell tower operators, Crown Castle in particular, for access to at least 80,000 US cell sites, a scale consistent with a fourth national wireless network. That report lifted tower stocks and hit AT&T, Verizon and T-Mobile. Bank of America raised its target on SPCX from $235 to $275 on October 22 with a Buy rating, JPMorgan reiterated Overweight saying the talks make Starlink Mobile more credible while noting the capital required, and Bernstein's Laurent Yoon called 80,000 sites broadly consistent with nationwide terrestrial scale. So the day ran premarket strength into a 9.1% close lower. A long tail of headline-only items sits around this name and is worth knowing exists: a $40 billion planned debt offering, Phillip Securities upgrading SPCX to Buy, $561 million reported from the Boring Company investment, Trump reportedly calling Musk to lift Ukraine Starlink restrictions (WSJ, plus two X posts on the same), Musk's public endorsement of the Tesla deal said to complicate talks, and several pieces on the merger's failure risk. Crown Castle up 7.5% premarket appears in a separate headline.
Other notable decliners
SNDK fell 8.5%, with headlines only: a note that the stock rose after a brutal sell-off ahead of its October 29 earnings, an options-volatility piece, a Form 4 from the chief legal officer, and a piece noting shares sank 6.9% despite a Mizuho $2,050 AI-storage target. VRT down 7.8% on a headline about an 8.65% fall despite a faster AI-factory deployment model. APH down 7.7%, with a GuruFocus headline calling it undervalued on GF Value after the drop. NBIS down 7.2% alongside headlines on a $3.5 billion bridge facility and neocloud debt fears, with BofA picking between CoreWeave and Nebius. ANET down 7.2% with CTO Kenneth Duda selling $7.8 million of stock. CRDO down 10.7% with only a Form 4 from director and CTO Chi Fung Cheng behind it. Gold and silver names AU and WPM were off 6.9% and 6.5%, with a headline noting gold fell below $4,000. MU down 6.3%, BWXT down 5.8% on Polish nuclear microreactor talks, DDOG down 5.6% with headlines on a proposed $4 billion acquisition of Upwind Security.
The gainers
ACN rose 7.7%, with headline-only coverage of Form 144 and Form 4 filings, a sale by Asia Pacific co-CEO Ryoji Sekido, and a GuruFocus note calling it still undervalued at a GF Score of 90. ADBE up 6.1%, with a headline that it reached its analyst consensus target. INTU up 5.7%, PAYX up 5.6%, CMCSA up 3.4% after mixed Q3 results with revenue described as flat, NFLX up 3.1% with a mixed set of analyst headlines including a Wolfe Research downgrade to Peer Perform and an Argus Buy with a lowered target, and AAPL up 1.2% with a headline noting an all-time high at $348.25 and a long run of ETF flow and 13F items that carry no real news.
Quiet names
The rest of the list is routine: broad ETF flow and 13F filings tagged mostly to AAPL and AVGO, option activity notices, a handful of Form 4s, and small moves in TSM (-4.5%), AVGO (-4.3%), ORCL (-2.8%), TEVA, PYPL, ONON and MRCY. Nothing there needs a second look today.
Forgent Power loses its CFO, stock down 21.3%
FPS is the worst mover on the list, down 21.3%. The company said on 22 October that CFO Ryan Fiedler is resigning to focus on family commitments and will move to a consulting role, with Amy Ard, currently EVP of finance, taking over. Two 8-K filings covering the officer change appear separately on the list. GuruFocus had the stock down 5.7% premarket at $29.90 on the news, so the full-day fall is far larger than the initial reaction and nothing in the material explains the rest of it. The same piece notes FPS trades on a price-to-sales of 5.82 against a historical median near 10.4, carries a GF Score of 16 out of 100, is unprofitable and cash-flow negative, and has seen $649.9m of insider selling over twelve months with no purchases. Market cap is $8.26bn; the business makes custom switchgear, transformers and power distribution units for data centres and utility substations.
Nokia beats on Q3 but falls 14.9%
Nokia is down 14.9% despite a Q3 that beat on every headline number. Revenue was €5.15bn against €5.07bn expected, up around 9% year on year, non-GAAP EPS €0.09 beat by €0.03, and adjusted operating profit came in at €605m versus the €454m analysts looked for, with comparable operating margin up 220 basis points to 11.7%. Reported margin was only 3.8% because of restructuring charges. Network Infrastructure sales rose 15%, IP Networks 43%, and sales to AI and cloud customers jumped 123%, with order intake up 118% to €1.5bn. Guidance was raised rather than cut: Q4 sales seen up 20% to 24% sequentially, full-year operating profit above the midpoint of prior guidance, and 2027 combined growth of 25% to 30%. Nokia also trimmed 2026 capex to €750-850m from €800-900m, fixed its tax rate outlook at 26%, widened the restructuring programme, and said the Infinera integration will finish by year-end 2026 with €200m of net synergies, a year early. A €0.03 quarterly dividend was declared, payable 5 November, ex-date 27 October. None of the eight Nokia items gives a reason for the share price falling on all this; the GuruFocus pieces repeatedly flag the stock as expensive against their own GF Value of $5.02 and note seven gurus trimming versus one adding.
Coherent down 12.5% on analyst cuts and a tech selloff
COHR fell 12.5%, and here the material does give a reason. Susquehanna cut its price target to $350 from $425, roughly 18%, while keeping a Positive rating, with the note landing the day before the open. That followed B. Riley trimming to $297 from $345 on 15 October and a Morningstar initiation on Coherent and Lumentum on 21 October that called current valuations elevated even though photonics is central to AI connectivity. The broad tape did not help: Nasdaq was down 2.2% and the S&P 500 1.4% during the session, and Coherent hit a session low of $209.46 against a prior close of $237.53. Peers moved the same way, with GE Vernova down 11.22% and Flex down 10.03% intraday. Fiscal Q1 results are scheduled for 3-4 November. GuruFocus separately notes a price-to-sales of 5.76 versus a 2.23 historical median, a GF Score of 78, $1.12bn of insider selling over the past year with no buying, and 12 of 13 tracked gurus trimming. A headline-only Nasdaq item lists COHR among notable Thursday option activity.
The AI infrastructure complex sold off together
Coherent's decline is part of a much wider move through the AI hardware and data centre names on this list, all headline-only. Astera Labs fell 11.1%, Credo 10.7%, Sandisk 8.5%, Vertiv 7.8%, Amphenol 7.7%, Nebius 7.2%, Micron 6.3%, TSMC 4.5%, Broadcom 4.3% and Oracle 2.8%. The connective tissue in the headlines is financing worry rather than demand: Investing.com's market wrap has the Nasdaq falling nearly 3% on elevated AI financing concerns, Nebius announced a $3.5bn bridge facility amid what one headline calls neocloud debt fears, and ORTEX data cited on X puts short sellers' October paper profits against AI data centre names at $6bn, with $2.94bn of that from NBIS alone and roughly $1.7bn from CoreWeave. Tower Semiconductor, down 11.5%, and TeraWulf, down 11.3%, sit in the same bucket. The only full-text pieces on those two are GuruFocus valuation notes written off the previous day's gains, TSEM up 3.1% to $189.55 and WULF up 6.2% to $12.76, so neither explains today's fall. The WULF options piece does note put/call at 0.16 against a 0.44 average and implied volatility at 104 ahead of earnings, plus $36.1m of insider selling against $0.4m of buying.
Vicor down 15.7% with no news behind it
VICR fell 15.7% and the only full-text item is a GuruFocus piece from 21 October describing a 4.5% rise to $213.42 the prior session. That article carries a GF Score of 79, GF Value of $72.69 against the then price, a P/E of 68.5x versus a 5-year median of 73.3x, and $424.1m of insider selling over twelve months. There is nothing in the material explaining today's drop.
SpaceX down 9.1% against a wall of positive headlines
SPCX is down 9.1%, which sits oddly against the volume of headline-only items on it. The Wall Street Journal, via several reposts, reports Trump called Musk and asked him to lift the speed restrictions on Ukraine's military-grade Starlink service. BofA raised its target to $275 from $235 after a Q3 beat and a stronger 2027 outlook, citing 35 launches in the quarter including Starship Flight 14; Barclays went to $300 from $254 and Pivotal Research to $260. Several items cover the Tesla-SpaceX merger talk, including Reuters reporting that Musk's public endorsement may complicate negotiations, pieces on China exposure and failure risk, and a claim the deal is intended to close before the end of Trump's term. An Investing.com headline asks directly why the stock is sliding today, but it is headline-only, so the reason is not in hand.
The green side: Accenture, Adobe, Comcast, Netflix, Apple
Accenture was up 7.7%, flagged in headlines as a 6.4% move on 1.5 times its own ATR20 on half its 20-day average volume, and as part of ETF inflows. Adobe rose 6.1%, with headlines on a weekly inverted head and shoulders and notable option activity. Comcast gained 3.4% after Q3 results, with headlines describing a beat on estimates, flat revenue, a maintained $0.33 quarterly dividend at a yield near 6% and close to a ten-year high, and separate Bloomberg reporting on significant planned job cuts. Netflix was up 3.1% amid a scatter of conflicting analyst moves, a Wolfe downgrade to Peer Perform, Argus keeping Buy with a lower target, Pivotal holding Hold at a lower target, and a bullish Deutsche Bank note. Apple added 1.2% and hit an all-time high at $348.25, with headlines on an iPhone Duo preorder surge prompting raised shipment targets per DigiTimes, limited in-store units on Friday, an AI Siri launch in South Korea, a copyright win over the Servant series, and Fortnite returning to the Australian App Store.
Smaller single-name items
Generac fell 7.5% and Datavault AI 7.4%, the latter alongside headlines on a letter of intent to buy a 19.9% stake in DataMEDS AI. Datadog was down 5.6%, with headlines reporting a proposed $4bn acquisition of Upwind Security and an Investing.com piece asking why the stock is sliding. Cognition Therapeutics fell 6.2% despite announcing FDA alignment on a pivotal Phase 3 design for zervimesine in dementia with Lewy bodies. TMC hit a 52-week low at $2.47. Everything else on the list is inside two percent and carries only routine ETF-flow, filing or analyst-initiation headlines.
Starfighters Space drops on a publicity item
FJET fell 9.2% on a day when the only news was promotional: the company said it will fly and display its F-104 Starfighters at the NASA-sponsored MAX POWER expo and airshow at Kennedy Space Center on November 7-8, with flight operations director Piercarlo Ciacchi piloting. Neither article links the announcement to the share move. The GuruFocus write-up on the same news is where the substance is, and it is unflattering: no meaningful revenue so price-to-sales is effectively nil, a GF Score of 14 out of 100, return on equity of -156.7%, and insiders selling $7.6 million of stock over twelve months with no buying at all. Offsetting that, the balance sheet is clean, with a current ratio of 11.94 and debt-to-equity of 0.02 on a $56 million market cap. The company's fleet came from Italy's retired F-104 inventory after 2004 and operates out of Kennedy and Midland, Texas, supporting hypersonic testing, microgravity work and pilot training.
SpaceX Q3 beat drives the tape
SPCX rose 7.8% and was the most active name on the day at 215.5 million shares. Q3 revenue was $14.58 billion, up 161% year on year against a Street figure near $12.87 billion, with EPS of $0.35 versus $0.13 expected and net income of $4.4 billion, a $5.5 billion swing from last year's $1.1 billion loss. Adjusted EBITDA was $8.81 billion. The mix is the story: the Super Intelligence segment did $7.6 billion, up 830% year on year and up $5 billion sequentially, making AI the largest revenue line for the first time at roughly 52% of sales, though $608 million of that came from the mid-quarter Cursor acquisition. Connectivity was $5.25 billion, up 69%, with 13.6 million Starlink consumer subscribers after 1.6 million net adds, ARPU of $69 a month and enterprise/government revenue up 91%. Space was $1.8 billion, up 84% sequentially but only 6% year on year, and swung to a $7 million operating loss from $259 million of income a year ago. Twelve customer launches in the quarter, 113 year to date, and Flight 14 reached orbit and deployed V3 satellites.
The capex and quality-of-earnings caveats
Management guided Q1 2027 revenue to $33-37 billion against a FactSet consensus near $22 billion, and is targeting a $100 billion annualised run-rate by December, with Musk floating $500 billion to $1 trillion of ARR by end-2027 and calling it a "crazy note" himself. The offset is spending. Q3 capex was $19.6 billion and Q4 is guided to $35-40 billion, roughly double. Nine-month operating cash flow of $13.1 billion fell short of capex by about $35 billion; cash stands at $51-53 billion against $38.8 billion of debt and finance leases. Part of the margin was one-off: Connectivity's 55% gross margin included about three points from tariff refunds, and management said Q4 should look more like Q2. Roughly $23.4 billion of Cursor-related employee equity will run through comp over three years. Backlog is $63 billion, about $42 billion expected within twelve months. Compute stood at 1.7 GW at quarter end, with 2.5-3.0 GW targeted by year-end and 10 GW-plus in 2027. KeyBanc stayed Sector Weight on free cash flow pressure, and Musk said Terafab aims for a first test chip around May or June 2027 with volume production targeted Q3 2028.
Analyst targets and options flow
The sell side moved in a cluster, with a very wide spread. JPMorgan's Doug Anmuth more than doubled his target to $500 from $240 at Overweight; Pivotal went to $260 from $230 on Buy, lifting its 2027 revenue forecast to $168 billion from $118 billion and its 2027 capex assumption to $320 billion from $186 billion, with a doubled $225 billion capital-raise assumption. TD Cowen went to $224 from $200, Goldman to $245, Cantor to $345, Needham held $250, Stifel $190, Piper Sandler stayed Neutral at $140, and Susquehanna raised to $176 at Neutral. Headlines also carry Morgan Stanley $300, Wells Fargo $274, Citi $240 with a 90-day upside catalyst watch, UBS $230, and Raymond James at Strong Buy with $800. Options volume hit 2.17 million contracts by midday, 60% calls, put-to-call around 0.65, with genuinely new positions in the April $215 calls and a Sept 2027 $290/$300 call spread. Three-month implied vol fell 0.90 points to 49.40% even as the stock rose.
Merger talk and the Skydance angle
Musk confirmed that Tesla and SpaceX have each formed special committees of independent directors to explore a combination, with him recused as a conflicted party. He explicitly said no terms have been agreed and that calling a deal certain would be "overstating it", noting Tesla would need approval from 50% of all shares outstanding, not just votes cast. Kalshi contracts price a 42% chance of a merger by March 2027 and 77% before 2028; Polymarket has 20% by end-2026 and 68% by end-2027. Separately, John Malone told the Paley summit he expects a global output deal plus an $8-10 billion SpaceX investment into Skydance to delever it, pointing to Larry Ellison's history of financing Musk; SKYD was up 10.63% and carries nearly $87 billion of debt after the Warner Bros. Discovery deal closed this month. Two further spillovers: CoreWeave's market-implied bankruptcy odds through 2028 dropped to 14% on the back of SpaceX's numbers, and United Airlines flagged Starlink as part of its premium strategy, with the United CEO quoted saying customers are already switching airlines for it and over 50% of flights crossing to Starlink this week.
Netflix sells off on ads and margin
NFLX fell 5.3% on a Q3 that beat on earnings but came with soft current-quarter revenue guidance and a trimmed advertising outlook. These are all headline-only, but the direction of the analyst response is unambiguous and unusually uniform: Needham downgraded to Hold on slowing growth, and price targets were cut across Evercore to $90, BofA to $90 on engagement concerns, Wedbush to $80, Guggenheim to $78 on the ad revenue miss, Rosenblatt to $71, plus cuts from Bernstein, Canaccord and Pivotal. BMO, TD Cowen, KeyBanc, Citizens and William Blair kept their ratings. One headline notes a new 52-week low.
Smaller movers
TeraWulf rose 6.3% and Credo 6.2%, the latter attributed in the headline to AI memory momentum and a $235 target. Vertiv was up 4.4% on an Nvidia design headline, Vicor 4.4% on a Zacks "Bull of the Day" piece, NetApp 3.5%, and Kodiak Gas Services 3.3% on news its CEO joined Reworld's board. Elsewhere the moves are under 3% and the items are routine: analyst target tweaks on Incyte, Coherent, Oscar/SMR, Revolution Medicines and Nebius, a BioCryst FDA clearance for an Orladeyo oral pellet, a Planet Labs NASA task order to evaluate Tanager hyperspectral data, an Accenture downgrade to Neutral at Baird after a near-100% rally, and a long run of mechanical ETF flow notices around Apple, Broadcom and Costco that carry no new information.
Tower Semiconductor drops 8.2%
TSEM was the biggest mover on the list, down 8.2% to close at $183.78 on October 20. The GuruFocus piece covering it offers no company-specific news behind the fall, only valuation framing: the stock sits 238.1% above the GF Value estimate of $54.35, trades at a trailing P/E of 72.5x against a five-year median of 24.5x, with a forward P/E of 26.8x. Its GF Score is 77/100, strong on financial strength, profitability and growth at 8/10 each, but 1/10 on valuation. Insiders sold $60 million of stock over the past twelve months with no buying. The 52-week range is $71.64 to $319.94, so this is a name that has already travelled a long way in both directions.
Vicor up 7.1% on record quarter
Vicor rose 7.1% to $204.14 and has the most actual substance behind it today. Q3 2026 revenue was $197.1 million, up 37.5% sequentially and 78.5% year over year. Advanced Products contributed $138.9 million (up 47.5% sequentially), Brick $58.3 million, and royalty revenue was $66.6 million, up 119.1% sequentially, partly from a non-recurring payment by a new licensee. Gross margin jumped to 68.3%, a 1,030 basis point sequential gain, driven by the royalty mix and better product margins. Net income was $63.3 million, GAAP diluted EPS $1.33, cash $513.1 million, one-year backlog $406 million and book-to-bill above 1. Legal expense rose about $11.1 million to $16.1 million, tied to contingent costs on royalties, and management expects legal to run near 20% of royalty revenue. For Q4 the company guided to roughly 10% sequential product revenue growth and at least $43 million of royalties assuming no new licences, declining to give a full total because of uncertainty over licence timing. CEO Patrizio Vinciarelli said capacity is the near-term constraint: Fab 1 is land-limited, two new sites (ChiP Fab-2 and Fab-3) have been bought, initial Fab 2 equipment arrives in Q2 2027, and the combination could raise capacity nearly fivefold, funded without raising capital. He said one major customer described demand doubling annually for several years, mostly AI-related. Separately, a GuruFocus valuation note flags the stock at 181.6% above its GF Value of $72.49, with a GF Score of 79/100, trailing P/E of 65.5x (below the five-year median of 73.6x), forward P/E 33.4x, and $424.1 million of insider selling in the past year with no buying. Worth noting the context in that piece: the stock fell 23.6% in the prior week and is up 86.3% year to date. There is also a headline-only Nasdaq item naming Vicor as Zacks' Bull of the Day.
Adobe up 3.9%, valuation note only
Adobe rose 3.9% to $256.73. The only item is a GuruFocus valuation piece with no news driver: the stock sits 52.2% below the GF Value estimate of $536.75, trades at 14.3x trailing earnings versus a five-year median of 37.1x, forward P/E 9.3x, and carries a GF Score of 88/100 with 10/10 for both profitability and growth but 2/10 on valuation. Insiders were net sellers of $48.8 million over the past year.
Three mid-single-digit movers with thin news
RGNX was up 3.5% and the only item is the transcript of an investor event held October 20, but the text available is just the opening remarks, which mention RGX-314 being near top-line data. Nothing substantive beyond that. DLO rose 3.1% to $15.18, again on a valuation note rather than news: GF Score 94/100 with growth at 10/10, price 26.5% below the GF Value of $20.65, trailing P/E 22.2x against a five-year median of 29.7x, and $16.0 million of net insider selling over twelve months. INTU gained 3.0%; a GuruFocus DCF piece puts earnings-based intrinsic value at $394.87 against the $335.29 price, with an FCF-based figure of $887.39 and GF Value of $833.51, built off current EPS of $17.25, a 16.7% ten-year growth assumption and a 12% discount rate. The same article notes the stock is down 48.7% year to date but up 11.2% over the past week.
AMC ticker is pointing at the wrong company
Three items tagged AMC (+3.4%) are all about Aditya Birla Sun Life Asset Management in India, not the US name — worth knowing before you act on that move. Q2 FY27 revenue rose about 4-5% to INR 526 crore, profit before tax fell 6.3% to INR 296 crore and profit after tax fell 8.3% to INR 221 crore, with the squeeze coming from a 33% jump in employee costs to INR 1,263 million on ESOP charges, wage inflation and hiring in the passive business. Total average AUM crossed INR 11.06 lakh crore, up 140% year over year, but that was driven almost entirely by a INR 6,528 billion EPFO mandate; core mutual fund QAAUM grew only 4% to INR 4,418 billion. ETF AUM rose 42% against industry growth near 27%. Management said costs should stay around Q2 levels and plans six new fund launches. The shares were quoted down 1.32% at 946.05 in that coverage.
Comcast DCF note
CMCSA rose 2.1%. A GuruFocus DCF piece puts earnings-based intrinsic value at $41.26 versus the $22.36 price, and an FCF-based value of $81.45, with GF Value at $36.77. Inputs are current EPS of $3.16, 8.1% ten-year growth, 12% discount rate. The caveat the article itself raises is a GF Score of 66/100 and a predictability rank of 2/5, which makes the DCF less reliable. The stock is down 15.9% year to date.
NuScale downgraded by Barclays, hits 52-week low
SMR fell 1.9%. Barclays analyst Christine Cho cut NuScale from Equal Weight to Underweight with a $5 target, down from $11, and the stock touched an intraday 52-week low of $5.33. The stated reason is slow contract progress, specifically the unresolved power purchase agreement with the Tennessee Valley Authority, which could push negotiations into 2027 and delay revenue recognition. The company remains unprofitable with TTM EPS of -$2.28, so there is no meaningful P/E; price-to-sales is around 87.8x versus a historical median near 52x, and GF Value is $3.71. GF Score is 47/100, strong on financial strength (8/10, current ratio 37.88, no debt) but 0/10 on both profitability and growth, with revenue down 6.2% over three years.
Netflix down 1.7% on soft guidance, heavy analyst cluster
There are over forty NFLX items and nearly all are headline-only, but the shape is consistent. Netflix beat Q3 earnings expectations and then fell, with the stated cause being cautious advertising and revenue guidance for Q4. Headlines list target cuts and rating changes from Pivotal Research (subscriber concerns), Guggenheim (ad revenue miss), Canaccord (execution concerns), Bernstein (2027 uncertainty), Bank of America (target to $90), Needham (downgraded to Hold), with maintained ratings from KeyBanc, Citizens, William Blair, and Wedbush's Ives at In Line and $75. The one Netflix item read in full is the Needham downgrade write-up, which says Laura Martin moved the stock from Buy to Hold on a more cautious view of growth amid competitive pressure, and notes a price of $68.69 against GF Value of $103.48, a trailing P/E of 21.64x versus a five-year median of 40.38x, a GF Score of 90/100 with profitability and growth both 10/10 but momentum at 2/10, and $13.2 million of insider selling in three months. Several headlines also reference a content leadership restructuring and a 52-week low.
Musk merger talk and the SpaceX block
SpaceX is flat on the day at -0.1% despite being the single largest item cluster on the list, almost all headline-only. The one full-text item, a GuruFocus morning brief, reports Musk confirming he is considering merging Tesla and SpaceX with both companies forming special committees, and SpaceX posting a 161% year-over-year revenue rise and a $4.4 billion quarterly profit on Starlink and AI growth. The same brief notes Boeing's 737 Max 10 received FAA certification, France's 10-year yield passed 5% for the first time since 2002, UK CPI rose to 3.5%, Anthropic reported a net loss above $80 billion for H1 2026, Micron settled its Taichung labour dispute in Taiwan, and Japanese export growth slowed to 16.7%. Headlines around SpaceX include large target increases (JPMorgan to $500 from $240, Goldman to $245, Cantor to $345) and a recurring Starlink-Ukraine access dispute. Given the quote shows no move, this is reading material rather than a trigger.
Smaller movers and the quiet remainder
ASTS was down 1.8% on an 8-K filing covering officer departures or appointments and compensatory arrangements — administrative, no detail in the filing summary. Cantor Fitzgerald initiated Modine Manufacturing at Overweight (MOD, -1.9%), headline only. Upstart was up 1.7% alongside an 8-K covering a material definitive agreement and a new direct financial obligation, with no further detail given. Beyond that the section is quiet: Micron (-1.0%) has the Taiwan labour agreement plus a $25.7 million stock sale by Scott Deboer, Accenture (+0.9%) was downgraded by Baird to neutral on valuation with the target raised to $252 and separately announced a physical AI safety suite with TUV SUD, and the remaining names are routine ETF flow notes, 13F-style buy/sell summaries and technical chart posts that carry no new information.
Revolution Medicines starts Phase 3 in lung cancer
RVMD is up 7.9% after announcing it has begun dosing patients in RASolve 308, a global Phase 3 trial of zoldonrasib, its oral RAS(ON) G12D-selective inhibitor, combined with pembrolizumab and platinum chemotherapy as first-line treatment in metastatic RAS G12D non-squamous NSCLC. The trial is randomised and double-blind against placebo plus the same standard regimen, with progression-free survival as the primary endpoint and overall survival, response rate, duration of response, safety and patient-reported outcomes as secondaries. The company frames the opportunity as a population with no approved targeted option: RAS G12D shows up in roughly 4% of NSCLC cases, against more than 229,000 US lung cancer diagnoses a year, and Revolution estimates about 61,000 new US patients annually across all RAS G12D cancers. Chief development officer Alan Sandler said earlier combination data showed encouraging preliminary antitumor activity and a favourable safety profile.
Eos Energy reaffirms, stock down anyway
EOSE is down 7.2%. The only item on it is a guidance roundup noting Eos reaffirmed fiscal 2026 revenue of $300 million to $350 million, unchanged from the range given on 5 August. Nothing in that piece explains the drop; it simply records the reaffirmation alongside Crown Holdings issuing new Q4 adjusted EPS guidance of $1.63 to $1.73.
Vicor Q3 blowout, record backlog, capacity build
Vicor is up 7.1% and is by far the most documented name here. Q3 revenue was $197.1 million, up 78.5% from $110.4 million a year ago and 37.5% sequentially, beating the roughly $183.7 million consensus. Royalty revenue was the swing factor, more than tripling to $66.6 million from $21.7 million, with product revenue at $130.5 million. Gross margin went to 68.3% from 57.5% a year earlier, and net income more than doubled to $63.3 million, or $1.33 a share. On EPS the reporting is inconsistent: Investing.com called $1.33 a beat against a $1.29 consensus, while GuruFocus framed it as a miss versus $1.37. Backlog rose 166% year over year to $406 million, up 7% sequentially, and the company flagged $100 million of bookings in the first half of Q4. Operating cash flow was $69.7 million against $38.5 million a year ago, and cash ended at $513.1 million, up 13.1% sequentially. CEO Patrizio Vinciarelli said the purchase of two additional sites within 30 miles of ChiP Fab-1 in Andover will give nearly a 5x capacity increase across three fabs. On the licensing side, Vicor granted its first Vertical Power Delivery licence to an AI OEM at Stage-2 unit royalty rates, and said the ITC's decision to open an investigation into VPD infringement is drawing licence enquiries from unlicensed OEMs and hyperscalers. Operating expenses rose to $62.5 million from $48.2 million, partly on contingency fees tied to that IP effort. Needham's N. Quinn Bolton reiterated Buy with a $350 target on 1 October, and Investing.com put the consensus target near $391.67 with EPS estimates revised up over 53% in the prior 60 days. Against that, GuruFocus repeatedly flags its own GF Value of $72.49 versus a price around $190 to $202, and notes $424.1 million of insider selling over twelve months with no insider buying, plus six of seven tracked gurus trimming. The Q3 call transcript and the 8-K are also in the list.
Datavault AI presentation at LD Micro
DVLT is up 4.7% after presenting at the LD Micro Main Event. CFO Brett Moyer described the company as a platform facilitator that helps customers value, tokenise, exchange, store and convert assets without owning them, comparing the model to eBay. He said four exchanges are live with one more coming and about 14 contracts under execution across real-world assets and data monetisation, with revenue from technology fees, transaction fees, cybersecurity and political donation processing. Partners cited include IBM watsonx, NYIAX, Fiserv, CLEAR, Trulioo, Houlihan Lokey and Available Infrastructure, plus CyberCatch, acquired in May 2024. The caveats were in the same presentation: the BankWise custody acquisition still needs Wyoming Bank Commissioner approval and is 12 to 14 months from full operation, the Fiserv fiat-conversion integration has one step left, and regulatory treatment of tokenised real-world assets under the CLARITY Act remains unsettled, with a London Perpetuals exchange held as a fallback. Moyer said the Available Infrastructure contract was locked in at January 2024 pricing and would cost more than 100% more today given GPU prices.
Oracle software spending survey
Oracle is up 1.2% and appears in a BNP Paribas note read in full. Analyst Stefan Slowinski said Oracle's software spending indicators improved in October after weakening in July, with Europe recovering and the trailing three-month spending score rising more than expected. Oracle's database services sold through AWS and Microsoft ranked among the three most sought-after products, with OCI and Fusion also improving. AWS had the strongest reading overall. Generative AI overtook cybersecurity as the top spending priority, which Slowinski suggested may mean AI tools are moving from experiments into budgets. The same survey was weak for Adobe and Zoom, with IBM ranked last. Adobe is nonetheless up 3.9% today, with its other items being Form 4 filings from Shantanu Narayen, interim CFO Steven Day and two other executives.
Headline-only movers worth a glance
Several names moved on items only read as headlines. Forgent is down 4.1% on a piece comparing it with Eaton as a data centre power stock. Red Cat is down 3.4%; Needham reiterated it at a $15.00 target, and CEO Jeffrey Thompson sold $676,500 of stock. Incyte is up 3.0% with president Pablo Cagnoni selling $297,779. Exelixis is up 2.7% and hit an all-time high at $63.39. UiPath is up 2.4% after CEO and chairman Daniel Dines sold 2.5 million shares, reported as $33.07 million. NuScale is down 2.0% after Barclays downgraded it to Underweight and cut its target on execution risks, with a separate piece asking why the stock was down 6%. Modine is down 1.9% after Cantor Fitzgerald initiated at Overweight. AST SpaceMobile is down 1.8% and touched a 52-week low at $39.85, with other headlines on a 60-plus ground gateway buildout and European spectrum. Datadog is down 1.5% despite a Bernstein upgrade to Outperform with a $350 target citing AI demand. Netflix is down 1.7% into tonight's results, with options reportedly pricing a 10% move, BMO cutting its target to $125, and headlines on a creative leadership reshuffle.
Apple, SpaceX and the quieter names
Apple is down 1.0% on a busy but mostly headline-level flow. Loop Capital downgraded it to Hold with the target cut to $330 from $370, on supply chain checks suggesting Apple will not recover 13 million iPhone shipments cut from 2026 plans, and MoffettNathanson kept Neutral while lowering its target to $283. Offsetting headlines cover up to $100 million committed to US titanium supply and new domestic suppliers for the iPhone 18 Pro, a 28 October product event, and a UK CMA consultation proposing lower Apple Pay fees and wider access to iPhone contactless. SpaceX is essentially flat at -0.1% but carries the largest headline cluster in the list, all pointing at tonight's Q3 report, Starlink, AI revenue, a Falcon 9 Bandwagon-5 launch and recurring Tesla merger speculation. The rest, including Broadcom, TSMC, Micron, Accenture, NetApp, Nebius, Sandisk, Coherent, Silence Therapeutics and the various Form 4 filings, moved around a percent or less and the items on them are routine.
Silence Therapeutics taken out by Merck KGaA
Silence Therapeutics is up 125.6%, and the reason is clean: Germany's Merck KGaA has agreed to buy the company in an all-cash deal, about $1.3 billion in equity value and $1.1 billion enterprise value. Holders get $20.00 per ADS, each ADS being three ordinary shares. That is a 130% premium to Friday's ADS close and an 82% premium to the 30-day VWAP of $10.99. Chairman and interim principal executive Iain Ross described it as the result of a competitive sale process delivering immediate and certain value. The structure is a UK scheme of arrangement under Part 26 of the Companies Act, needs shareholder approval, sanction by the High Court in England and Wales and regulatory clearances, and is expected to close in Q1 2027. The board approved unanimously and holders of roughly 14% of voting power have signed support agreements. Merck is buying the RNA platform that silences disease-causing protein production: lead asset divesiran in polycythemia vera, plus zerlasiran for elevated Lp(a). GuruFocus makes the point that from here the remaining return is tied to deal completion rather than clinical data.
Memory names bounce back, SanDisk and Micron
SanDisk is up 5.5% and Micron up 3.0%, a recovery from last week's memory selloff rather than anything new on fundamentals. GuruFocus notes Nasdaq 100 futures were up about 1.2% and S&P futures about 0.7% premarket, with falling oil easing inflation and rate worries, plus renewed attention on Nvidia reportedly asking Micron, SK Hynix and Samsung to use TSMC's 3nm process for base dies in custom HBM. SK Hynix gained 4.1%. Average analyst targets cited imply roughly 80% upside for Micron, 70% for SanDisk, 87% for SK Hynix. Context on how far SNDK fell: a separate GuruFocus piece describes a 17.9% single-day drop on a hotter-than-expected CPI print that pushed the VIX up nearly 30% to a four-month high, against a 857.8% first-half gain. SNDK trades at 19.03x trailing earnings versus a five-year median of 23.74x, GF Score 45, insiders sold $131.6 million over twelve months with no buying. The competitive overhang is China's ChangXin Memory, which fell 7.77% in Shanghai despite guiding to nine-month 2026 revenue of 265-270 billion yuan against 32.08 billion a year earlier and net profit of 131-132.5 billion. Western Digital, which reports fiscal Q1 late Thursday, led the S&P 500 up 6.1% to 352.21 per IBD. One TradingView post flagged a systematic long bracket order on SNDK at 1371.12 off an RSI cross above 30, stop 982.07, target 2927.36 — that's a retail chart setup, not news.
Datadog upgraded at Bernstein on AI token demand
Datadog is up 5.4%, driven by Bernstein's Peter Weed upgrading to Outperform from Market Perform with the target lifted to $350 from $237, and FY26/FY27 EPS estimates moved to $2.82 and $4.00. The notable thing is that Bernstein is reversing its own downgrade from last quarter, which had cited roughly $100 million of ARR cut from Datadog's largest "Born in AI" customer and weakness in the traditional base that makes up about 85% of revenue. Bernstein had expected net new ARR growth to slow to 20-30% in 2027 from 80-90% this year. That slowdown hasn't appeared: alternative data shows enterprise token consumption at the largest AI labs grew at least 50% quarter over quarter, possibly faster at smaller AI-native customers, with consumer agent launches Muse and Dots cited. Jefferies went the other way, trimming its target to $280 from $300. Schaeffer's notes the move snaps a five-day losing streak after the October 12 record high of $300.68, with the stock up 93.5% year to date, 42 of 46 covering brokers at buy or better, and a 10-day put/call ratio of 1.11 in the 91st percentile. GuruFocus flags the counterweight: GF Value $206.84 against a price around $260, so roughly 26% overvalued, trailing P/E of 531x versus a five-year median near 420x, GF Score 83 with growth at 10/10 but profitability 4/10, and insiders selling $905.8 million over twelve months with no buying. Q3 results land November 4. A TradingView write-up covers the same tension, arguing stock-based compensation and dilution matter as much as free cash flow growth here.
Arista, Accenture and TeraWulf valuation screens
Arista is up 3.4% to $182.95, though still down 13.2% on the week and 8.2% on the month, with GuruFocus putting it 7.5% above GF Value of $170.16 on a 57.7x trailing P/E against a 42.7x five-year median, a near-perfect GF Score of 99, and insiders having sold $1.50 billion over twelve months with no buying. Accenture is up 3.2% to $236.93 and screens the opposite way, 32.5% below GF Value of $351.20, with a 17.5x trailing P/E versus a 27.2x median and GF Score 87, though insiders sold $19.1 million and bought nothing. TeraWulf is up 3.3% to $12.06 but GuruFocus calls it 102% above GF Value of $5.97, GF Score 39, growth 0/10, trailing P/E of 180x against a 21.2x median, and net insider selling of $35.6 million over the year. Separately and headline-only, Accenture is reported to be eyeing a $1.5 billion exit in a key market as its AI strategy shifts.
Headline-only movers worth a glance
Several names moved on things I only have the headline for. NuScale is down 2.4% after Barclays downgraded it to Underweight and cut the target on execution risks, with a separate piece asking why the stock was down 6% intraday. Apple is down 0.2%, with Loop Capital downgrading to Hold and cutting its target to $330 from $370, the stated reason being that supply chain checks suggest Apple won't recover 13 million iPhone shipments cut from 2026 plans; separately Apple has set a product event for October 28 and committed up to $100 million for US titanium. AST SpaceMobile is up 3.0% on a European satellite spectrum collaboration. Nebius is up 2.9% alongside a broader neocloud rebound and a Truist $355 call. Revolution Medicines is up 2.4% having started a Phase 3 lung cancer trial, with Truist raising its target to $241. UiPath is up 2.1% despite CEO Daniel Dines selling 2.5 million shares for $33.07 million and Hedgeye naming it a top short. SpaceX is up 1.3% ahead of Q3 earnings, with heavy flow around Musk's pledge to gift SpaceX stock to children via Trump Accounts and Kalshi pricing a Tesla-SpaceX merger before February 2027 at 67%, up from about 30% earlier this month. Netflix is down 1.0% into tonight's after-close report, consensus EPS $0.82, amid back-to-back senior departures including film chief Dan Lin. Vicor is essentially flat at -0.4% after a Q3 earnings beat that reportedly sent shares up 5%.
Oil backdrop behind the tape
One item tagged to SLN is actually an OilPrice opinion piece by James Durso arguing a US ground invasion of Iran would be a strategic catastrophe, pointing to Iran's size, terrain and IRGC asymmetric preparations, and saying an invasion could push oil toward $200 a barrel. It has nothing to do with Silence Therapeutics, but the surrounding price board is relevant to the day: WTI around 100.5 and Brent around 111, up on tanker attacks in the Persian Gulf, Asian LNG past $30, and Canadian inflation at 3.1% with fuel oil up 58%. Falling oil in the US session was cited as part of why tech bounced.